NCTX
Phase 2- Indications
- CT imaging contrast agent
Company intelligence / Profile preview
Marval Pharma Ltd.
Netanya, Israelpmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Marval Pharma developed biomedical imaging agents, including liposomal nanocarriers designed to deliver CT contrast agents for the diagnosis of acute chest pain. There is no public information about clinical trial results or commercialized products. The company’s trademarks related to diagnostic reagents and contrast media have been abandoned or cancelled as of 2020, suggesting inactivity or discontinuation of product development[6].
- Therapeutic areas
- Cardiovascular
- Modalities
- Biomedical imaging agentsLiposomal nanocarriers for CT contrast agents
- Industry
- Medical Imaging
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Marval Pharma Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marval Pharma Ltd..